Emvision Medical Devices Shares Decline Amid Sector‑Wide Volatility
Emvision Medical Devices Limited (ticker EMV.AX) finished the 24‑hour trading window at 01:52 AM Central Europe on Wednesday, 21 March 2026, down 2.8 % from its previous close. At the time of reporting, one share was available for purchase at approximately AUD 1.56 on major Australian exchanges.
The company’s shares are widely held, with a current free float of 95.6 million shares. Market‑capitalisation stands at AUD 149.7 million, and the volume of trades in the last 24 hours was roughly AUD 44.4 k. Since the close of the previous month, the stock has declined 6.85 %, reflecting a broader trend of consolidation in the medical‑device sector.
Technical Snapshot
- 200‑day simple moving average: AUD 1.69
- 52‑week high: AUD 1.96 (recorded on 05 Aug 2026)
- 52‑week low: AUD 1.47 (recorded on 14 Jul 2026)
The current price sits below the 200‑day average, suggesting short‑term bearish sentiment, while the 52‑week range indicates a modest trading band for the year.
Peer Performance
Emvision’s performance can be contextualised by examining the recent movements of other ASX‑listed medical and energy companies:
| Company | Ticker | 24‑hr change | Current price | Market cap |
|---|---|---|---|---|
| Optiscan Imaging | OIL.AX | ‑6.06 % | AUD 0.16 | AUD 172.3 million |
| Acusensus | ACE.AX | +6.93 % | AUD 1.09 | AUD 173 million |
| Actinogen Medical | ACW.AX | +2.22 % | AUD 0.05 | AUD 173.2 million |
| Carnarvon Energy | CVN.AX | +5.00 % | AUD 0.10 | AUD 178.9 million |
| Polymetals | POL.AX | ‑3.45 % | AUD 0.55 | AUD 179.1 million |
While some peers, such as Acusensus and Actinogen Medical, have experienced gains, others—particularly Optiscan Imaging and Polymetals—have mirrored Emvision’s downward drift. The mixed performance underscores the sector’s volatility and the influence of company‑specific fundamentals on share prices.
Company Overview
Emvision Medical Devices Ltd is headquartered in Brisbane, Australia, and specialises in healthcare testing services, with a particular focus on medical imaging for the brain and other organs. The firm operates exclusively within Australia, offering its services through the company’s website, www.emvision.com.au . Its stock is listed on the ASX All Markets, providing investors with exposure to the domestic medical‑device industry.
Outlook
Analysts are monitoring Emvision’s ability to sustain its market‑cap and to navigate the competitive landscape of medical imaging. The current price level, situated below the 200‑day moving average, suggests that a reversal may be contingent on positive earnings releases or strategic partnerships. Investors should remain cognisant of the broader sector trends and the company’s recent performance relative to its peers.
